利用基因组编辑在人类造血干细胞中诱导t(9;11)染色体易位构建MLL白血病模型
该研究利用转录激活样效应核酸酶在CD34+人脐血细胞中生成t(9;11)染色体易位,获得表达MLL-AF9及AF9-MLL融合产物的细胞;特定细胞因子组合使初始罕见的易位细胞单克隆生长并永生化,移植至免疫缺陷小鼠后48周内诱导出髓系白血病,其病理和分子特征与患者MLL重排白血病广泛重叠。
要点
- 基因组编辑可在人CD34+脐血细胞中诱导t(9;11)易位并表达MLL-AF9融合。
- 特定细胞因子组合使易位细胞单克隆生长并永生化,伴MLL靶基因和CD9高表达。
- 移植后48周内诱导髓系白血病,靶向外显子组和全基因组RNA测序未发现继发性致病突变。
核心结论
- 基因组编辑可在人造血干/祖细胞中诱导致病性t(9;11)易位,移植后48周内诱导出与患者MLL重排白血病病理和分子特征广泛重叠的髓系白血病。
- 靶向外显子组测序和全基因组RNA测序分析未发现继发性致病突变,提示t(9;11)易位对于人造血干/祖细胞白血病发生具有遗传充分性。
- 该体系可在体内模拟人急性MLL重排白血病,反映该病的遗传简单性,并为生物学和疾病建模提供实验平台。
研究设计与样本
- 研究利用转录激活样效应核酸酶在CD34+人脐血细胞中通过靶向DNA双链断裂诱导t(9;11)染色体易位,生成编码MLL-AF9及交互AF9-MLL融合产物的细胞。
- 通过特定细胞因子组合实现初始罕见易位细胞的单克隆生长和永生化,并以MLL靶基因表达升高、表面CD9高表达和集落形成能力增强进行区分。
- 将永生化细胞移植至免疫缺陷小鼠,观察白血病发生,并行靶向外显子组测序和全基因组RNA测序分析。
主要发现
- 特定细胞因子组合使初始罕见的t(9;11)易位细胞实现单克隆生长和永生化,这些细胞表现为MLL靶基因表达升高、表面CD9高表达和集落形成能力增强。
- 永生化细胞移植至免疫缺陷小鼠后48周内诱导出髓系白血病,其病理和分子特征与初诊患者MLL重排白血病广泛重叠。
- 靶向外显子组测序和全基因组RNA测序分析未发现继发性致病突变,提示t(9;11)易位对于人造血干/祖细胞白血病发生具有遗传充分性。
临床怎么用
- 作者认为,基因组编辑可在体内模拟人急性MLL重排白血病,反映该病的遗传简单性,并为生物学和疾病建模应用提供实验平台。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genome editing provides a potential approach to model de novo leukemogenesis in primary human hematopoietic stem and progenitor cells (HSPCs) through induction of chromosomal translocations by targeted DNA double-strand breaks. However, very low efficiency of translocations and lack of markers for translocated cells serve as barriers to their characterization and model development. Here, we used transcription activator-like effector nucleases to generate t(9;11) chromosomal translocations encoding MLL-AF9 and reciprocal AF9-MLL fusion products in CD34+ human cord blood cells. Selected cytokine combinations enabled monoclonal outgrowth and immortalization of initially rare translocated cells, which were distinguished by elevated MLL target gene expression, high surface CD9 expression, and increased colony-forming ability. Subsequent transplantation into immune-compromised mice induced myeloid leukemias within 48 weeks, whose pathologic and molecular features extensively overlap with de novo patient MLL-rearranged leukemias. No secondary pathogenic mutations were revealed by targeted exome sequencing and whole genome RNA-sequencing analyses, suggesting the genetic sufficiency of t(9;11) translocation for leukemia development from human HSPCs. Thus, genome editing enables modeling of human acute MLL-rearranged leukemia in vivo, reflecting the genetic simplicity of this disease, and provides an experimental platform for biological and disease-modeling applications.
引用
- Schneidawind C, Jeong J, Schneidawind D, et al. MLL leukemia induction by t(9;11) chromosomal translocation in human hematopoietic stem cells using genome editing. Blood Adv. 2018. PMID: 29650777. doi:10.1182/bloodadvances.2017013748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。